These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 35095898)

  • 1. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
    Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in colorectal cancer: rationale, challenges and potential.
    Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
    Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
    Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes.
    Wu W; Liu Y; Zeng S; Han Y; Shen H
    J Hematol Oncol; 2021 Oct; 14(1):160. PubMed ID: 34620200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
    Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
    Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
    BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.